Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284036 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects
A Phase 1 study, sponsored by Ablynx, a Sanofi company.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT01284036 is a Phase 1 study that has completed, run by Ablynx, a Sanofi company. The registered enrollment target is 63 participants.
The verdict
NCT01284036, a Phase 1 study, has completed, sponsored by Ablynx, a Sanofi company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to find the safety and side effects of investigational drug in healthy volunteers. See how quickly investigational drug enters the bloodstream, is distributed in the body, broken down and removed in healthy male and female volunteers. See if your body makes antibodies to this investigational drug (how your immune system responds).
Interventions
- DRUG PF-05230905
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01284036
The ClinicalTrials.gov registry entry for NCT01284036 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ablynx, a Sanofi company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-05230905 is the first listed.
NCT01284036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01284036 about?
NCT01284036 is a clinical study titled "A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects". The purpose of this study is to find the safety and side effects of investigational drug in healthy volunteers. See how quickly investigational drug enters the bloodstream, is distributed in the body, broken down and removed in healthy male and female volunteers. See if your body makes antibodies to...
What is the current status of trial NCT01284036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2010-10. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01284036?
The interventions under investigation include: PF-05230905 (DRUG).
Who is sponsoring clinical trial NCT01284036?
This trial is sponsored by Ablynx, a Sanofi company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.